Celsion Corporation to Hold Second Quarter 2021 Financial Results and Business Update Conference Call on Thursday, August 12, 2021
August 05 2021 - 7:00AM
Celsion Corporation (NASDAQ:
CLSN), a clinical-stage development company focused on
DNA-based immunotherapy and next-generation vaccines, announced
today that the Company will host a conference call at 11:00 a.m.
EDT on Thursday, August 12, 2021 to discuss financial results for
the second quarter ended June 30, 2021 and provide an update on
product development programs with GEN-1, a DNA-based immunotherapy,
currently in Phase II development for the localized treatment of
advanced ovarian cancer and PLACCINE, a proprietary synthetic,
non-viral vaccine delivery technology currently in preclinical
studies. Celsion has two platform technologies for the development
of novel nucleic acid-based immunotherapies and next generation
infectious vaccines.
To participate in the call, interested parties
may dial 1-800-353-6461 (Toll-Free/North America) or 1-334-323-0501
(International/Toll) and ask for the Celsion Corporation Second
Quarter 2021 Earnings Call (Conference Code: 2901622) to register
ten minutes before the call is scheduled to begin. The call will
also be broadcast live on the internet at www.celsion.com. The call
will be archived for replay on Thursday, August 12, 2021 and will
remain available until August 26, 2021. The replay can be accessed
at 1-719-457-0820 or 1-888-203-1112 using Conference ID: 2901622.
An audio replay of the call will also be available on the Company's
website, www.celsion.com, for 90 days after 2:00 p.m. EDT Thursday,
August 12, 2021.
About Celsion
Corporation
Celsion is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative cancer treatments, including immunotherapies and
DNA-based therapies; and a platform for the development of nucleic
acid vaccines currently focused on SARS-CoV2. The company’s product
pipeline includes GEN-1, a DNA-based immunotherapy for the
localized treatment of ovarian cancer. ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, is under
investigator-sponsored development for several cancer indications.
Celsion also has two platform technologies for the development of
novel nucleic acid-based immunotherapies and other anti-cancer DNA
or RNA therapies. Both are novel synthetic, non-viral vectors with
demonstrated capability in nucleic acid cellular transfection. For
more information on Celsion, visit www.celsion.com.
Forward-looking Statements
Forward-looking statements in this news release
are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
subject to a number of risks and uncertainties, many of which are
difficult to predict, including, unforeseen changes in the course
of research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data, particularly in small subgroups that are not statistically
significant; FDA and regulatory uncertainties and risks; the
significant expense, time and risk of failure of conducting
clinical trials; the need for Celsion to evaluate its future
development plans; possible acquisitions or licenses of other
technologies, assets or businesses; possible actions by customers,
suppliers, competitors or regulatory authorities; and other risks
detailed from time to time in the Celsion's periodic filings with
the Securities and Exchange Commission. Celsion assumes no
obligation to update or supplement forward-looking statements that
become untrue because of subsequent events, new information or
otherwise.
Celsion Investor ContactJeffrey W.
Church609-482-2455 jchurch@celsion.com
LHA Investor RelationsKim Sutton
Golodetz212-838-3777kgolodetz@lhai.com
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2024 to May 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From May 2023 to May 2024